Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s): FENC

Healthcare Biotechnology

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs

Bullboard Posts

Comment by dollarhunteron Jan 27, 2004 9:21pm

209 Views

Post# 6962783

RE: another supper news

Yes this is super news but can't be the reason for the recent upsurg in the share price. Somthing else must be on the horizon. I know we all figure it's possible results from phase one trials that have been ongoing for over 13 months to date or mabey a phase two announcment but can anyone say for sure? DH

Bullboard Posts

This battery metals stock is on a path to the global stage